Published: May 24, 2026 | Category: Virology & Vaccine Research
The World Health Organization declared the current Ebola outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern (PHEIC) on May 17, 2026. With over 500 suspected cases and 130+ deaths reported, research teams worldwide are mobilizing rapidly. ProSci offers a portfolio of Ebola virus antibodies designed to support diagnostic development, vaccine research, and surveillance efforts during this critical response period.
This outbreak, now the 17th recorded in the DRC, is caused by the Bundibugyo ebolavirus — a less common strain than the Zaire ebolavirus that drove the devastating 2014 West Africa epidemic. The Bundibugyo strain presents unique challenges: existing treatments and vaccines were developed primarily against the Zaire strain, and their cross-reactivity with Bundibugyo remains an active area of investigation.
The CDC has implemented enhanced travel screening and entry restrictions, while research institutions are moving quickly to support assay development, surveillance, and therapeutic research. Fast-moving outbreak situations place significant pressure on research teams to validate assays, study viral proteins, and advance countermeasure development as efficiently as possible.
High-quality, application-ready antibodies remain essential tools in outbreak response efforts. ProSci offers Ebola virus antibodies targeting key viral proteins involved in viral entry, replication, and immune recognition.
View our complete portfolio of Ebola virus antibodies for your research applications.
Our Ebola antibody portfolio includes antibodies against important targets including glycoprotein (GP) and nucleoprotein (NP) — the primary antigens studied in outbreak-response research environments.
The Ebola virus glycoprotein (GP) is the only protein present on the viral surface and on infected cells. It mediates viral entry into host cells and is the primary target for neutralizing antibodies. The GP exists in several forms, including a transmembrane form incorporated into virions and a secreted soluble form (sGP) that appears early in infection.
The nucleoprotein (NP) encapsidates the viral RNA genome and is highly immunogenic, making it a valuable target for diagnostic assay development and surveillance studies. Both proteins are critical for understanding viral pathogenesis and developing effective countermeasures.
Ebola virus research spans multiple disciplines, and validated antibodies can help researchers:
During emerging infectious disease events, research timelines accelerate dramatically. Scientists need reagents that support rapid assay development, reproducibility, and reliable performance across multiple workflows. Trial sizes are available for many products, helping researchers evaluate candidates during early-stage assay and workflow development.
ProSci Ebola antibodies are available directly through our website and through distribution partners including Fisher Scientific.
Our portfolio is designed to support researchers working in academic virology labs, public health and surveillance groups, vaccine developers, diagnostic assay development teams, biotech and pharmaceutical research programs, and CROs supporting infectious disease initiatives.
While outbreaks create serious global health challenges, they also highlight the critical importance of rapid scientific collaboration and access to dependable research tools. For over 28 years, ProSci has supported researchers working on emerging infectious diseases — from HIV and influenza to coronaviruses and filoviruses.
ProSci remains committed to supporting the scientific community with high-quality antibodies and responsive service for emerging infectious disease research. To learn more about our infectious disease antibodies and research support capabilities, contact our team or explore our Ebola antibody catalog.
Share this post:
